Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1Other solid neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Recurrence 1Lymphoma, Follicular 1

Interventions

Cyclophosphamide 71Rituximab 53Specimen Handling 47Biopsy 40Doxorubicin 39Vincristine 38Magnetic Resonance Spectroscopy 36Prednisone 35venetoclax 28obinutuzumab 26fludarabine 26Methotrexate 22ibrutinib 21Cytarabine 21Dexamethasone 20Lenalidomide 19Etoposide 18merphos 17blinatumomab 17zanubrutinib 15prednylidene 15fludarabine phosphate 15deltacortene 15acalabrutinib 15X-Rays 14Mercaptopurine 14Bendamustine Hydrochloride 14pegaspargase 13Calcium Dobesilate 13Nivolumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Itraconazole × Lymphoid × 30 days × Clear all
NCT03460977 2026-06-05

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Pfizer

Phase 1 Recruiting
453 enrolled
LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡